Cartesian Therapeutics, Inc. Common Stock (RNAC) Stock Price

RNACStock

$6.27−33.44%52W

Market Cap$189.70M

P/E—

PEG Ratio—

Div yield—

Beta0.74

RNAC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-11.17%

Price vs S&P 500 (4W)-19.71%

VGM Score26.48

Book Value / Share (Quarterly)$0.03

P/TBV (Annual)2.30x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-70.66%

Cash Flow / Share (Quarterly)$-2.62

Price vs S&P 500 (YTD)-24.96%

Net Profit Margin (TTM)-8550.65%

EPS (TTM)$-5.87

10-Day Avg Trading Volume0.15M

EPS Excl Extra (TTM)$-5.87

Revenue Growth (5Y)-29.96%

EPS (Annual)$-5.02

ROI (Annual)29.46%

Net Profit Margin (5Y Avg)-1140.15%

Cash / Share (Quarterly)$4.91

Revenue Growth QoQ (YoY)-92.91%

ROA (Last FY)-43.96%

Revenue Growth TTM (YoY)-20.68%

EBITD / Share (TTM)$-5.62

ROE (5Y Avg)-185.49%

Operating Margin (TTM)-8338.87%

Cash Flow / Share (Annual)$-3.05

P/B Ratio252.26x

P/B Ratio (Quarterly)512.19x

Net Income / Employee (Annual)$-1,737,400

EV / Revenue (TTM)53.49x

Net Interest Coverage (TTM)-0.62x

ROA (TTM)-47.61%

EPS Growth QoQ (YoY)-12.09%

EPS Incl Extra (Annual)$-5.02

Current Ratio (Annual)8.65x

Quick Ratio (Quarterly)7.19x

3-Month Avg Trading Volume0.18M

52-Week Price Return-33.44%

EV / Free Cash Flow (Annual)3.02x

Revenue / Employee (TTM)$19,700

Tangible BV / Share (Quarterly)$0.39

P/S Ratio (Annual)67.82x

Asset Turnover (Annual)0.01x

52-Week High$11.00

Operating Margin (5Y Avg)-1112.90%

EPS Excl Extra (Annual)$-5.02

CapEx CAGR (5Y)46.26%

Tangible BV CAGR (5Y)12.61%

26-Week Price Return-1.26%

Quick Ratio (Annual)8.45x

13-Week Price Return-24.09%

Total Debt / Equity (Annual)0.28x

Current Ratio (Quarterly)7.48x

Enterprise Value$94.95M

Revenue / Share Growth (5Y)-53.44%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-23.36%

Revenue / Employee (Annual)$37,300

Pretax Margin (Annual)-4987.31%

Cash / Share (Annual)$4.81

3-Month Return Std Dev48.11%

Net Income / Employee (TTM)$-2,025,200

ROE (Last FY)37.71%

Net Interest Coverage (Annual)4.68x

EPS Basic Excl Extra (Annual)$-5.02

P/FCF (TTM)25.32x

Receivables Turnover (TTM)5.37x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-5.87

Receivables Turnover (Annual)2.82x

ROI (TTM)-3215.82%

P/S Ratio (TTM)106.87x

Pretax Margin (5Y Avg)-1216.71%

Revenue / Share (Annual)$0.11

Tangible BV / Share (Annual)$0.61

Price vs S&P 500 (52W)-48.97%

Year-to-Date Return-13.04%

5-Day Price Return-10.30%

EPS Normalized (Annual)$-5.02

ROA (5Y Avg)-25.70%

Net Profit Margin (Annual)-4658.63%

Month-to-Date Return-13.04%

Cash Flow / Share (TTM)$-0.23

EBITD / Share (Annual)$-5.41

Operating Margin (Annual)-5127.10%

LT Debt / Equity (Annual)0.19x

ROI (5Y Avg)-74.06%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-5.87

P/TBV (Quarterly)3.57x

P/B Ratio (Annual)2.17x

Pretax Margin (TTM)-9068.56%

Book Value / Share (Annual)$0.61

Price vs S&P 500 (13W)-26.78%

Beta0.74x

P/FCF (Annual)5.57x

Revenue / Share (TTM)$0.05

ROE (TTM)-3215.82%

52-Week Low$5.60

vGradeF

gGradeF

mGradeC

vgmGradeD

RNAC Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$0.65	-$0.96	-48.27%(-$0.31)
Q1 2026	Apr 30, 2026	-$0.70	-$0.95	-35.51%(-$0.25)
Q4 2025	Mar 9, 2026	-$0.79	-$2.71	-242.59%(-$1.92)
Q3 2025	Nov 6, 2025	-$0.63	-$0.73	-16.00%(-$0.10)
Q2 2025	Aug 7, 2025	-$0.65	-$0.77	-18.83%(-$0.12)

RNAC Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.29

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
RNACCartesian Therapeutics, Inc. Common Stock	F	F	C	106.9x	-20.7%	—	—	$6.27
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Cartesian Therapeutics, Inc. Common Stock

Cartesian Therapeutics is a clinical-stage biopharmaceutical company developing mRNA-based therapies to induce immune tolerance. The company's ImmTOR platform uses proprietary manufacturing and cellular engineering technology to mitigate unwanted immune responses, particularly in autoimmune and transplant-related conditions. This approach represents a novel mechanism for treating conditions where immune suppression needs to be targeted rather than systemic.